CN114181311B

CN114181311B - Fully human anti-DLL 3 scFv and application thereof in CART cell therapy

Info

Publication number: CN114181311B
Application number: CN202111560685.1A
Authority: CN
Inventors: 朱红佳; 徐南; 康立清; 余宙; 沈文燕; 闫志强; 谭靖雯; 叶晶; 贾裕杰; 方小燕
Original assignee: East China Normal University; Shanghai Unicar Therapy Bio Medicine Technology Co Ltd
Current assignee: East China Normal University; Shanghai Unicar Therapy Bio Medicine Technology Co Ltd
Priority date: 2021-12-20
Filing date: 2021-12-20
Publication date: 2023-06-20
Anticipated expiration: 2041-12-20
Also published as: CN114181311A

Abstract

The invention discloses an anti-DLL 3 scFv which can specifically bind to DLL3; and the complementarity determining region sequences of the two heavy and light chains are given. The invention also discloses a plasmid containing the anti-DLL 3 scFv, the related nucleotide sequence of the anti-DLL 3 CAR and a recombinant lentiviral vector. The invention verifies the specific killing of the anti-DLL 3 CAR-T on the DLL3 positive tumor cells and the cytokine secretion of the anti-DLL 3 CAR-T after the target cells are stimulated; lays a foundation for developing the full-human DLL3 antibody and the later-stage DLL3 antibody to clinical development.

Description

Fully human anti-DLL 3 scFv and application thereof in CART cell therapy

Technical Field

The invention belongs to the field of biological medicine, and in particular relates to an anti-DLL 3 single-chain antibody (scFv), a chimeric antigen antibody (CAR), a carrier, cells, a preparation method and application.

Background

Lung cancer is the most frequently occurring malignancy worldwide, and has become the biggest cancer killer worldwide. Worldwide Health Organization (WHO) international cancer research Institute (IARC) published the most recent global cancer data in 2020, with lung cancer mortality still being the first. Lung cancer is largely divided into two major categories: non-small cell lung cancer (NSCLC) and Small Cell Lung Cancer (SCLC), wherein NSCLC accounts for about 85% of all lung cancer cases, SCLC accounts for 15%. Because of the extremely aggressive nature, most lung cancer patients are advanced at the time of diagnosis, and these patients may die within 1 to 2 years without the corresponding precise therapeutic drug, with five-year survival rates of less than 15%.

In the field of lung cancer, the success of immunotherapy based on PD- (L) 1 mab has been dominant in recent years in the field of lung cancer, especially NSCLC, and other classes of immunotherapy continue to occupy the focus of lung cancer news, including combination therapy. There are 4 types of cancer immunotherapy based on PD1/PDL1 immune checkpoint that have been approved by FDA for the treatment of non-small cell lung cancer, wherein BMS product PD-1 inhibitor Opdivo, rocark PD-L1 inhibitor tecantriq, merck & Co samsaron PD-1 inhibitor pam mab Keytruda were approved by FDA for the treatment of small cell lung cancer at 2018, 2019, 3 and 2019, 6, respectively. Not only is immunotherapy greatly advanced in the field of lung cancer, but also research on targeted therapy of lung cancer is always a research hotspot, and targeted drugs are divided into two main categories, namely antibody drugs and small molecule inhibitor drugs. The small molecule inhibitor drug targets the driver gene mutation on lung cancer cells, and from the current clinical practice application, the main gene mutation in lung cancer comprises: EGFR, ALK, ROS1, BRAF, MET, ROS, RET, KRAS, HER2, etc., there are currently 5 small molecule inhibitors targeting EGFR (gefitinib, etc.) approved for the treatment of NSCLC, EGFR-TKI has become the first line standard treatment regimen for EGFRm+advanced NSCLC patients. For lung cancer patients with positive sensitive gene mutation, the targeted small molecule inhibitor greatly improves the overall remission rate of NSCLC. Small molecule inhibitors are typically targeted to downstream signaling pathways of cell transduction, while monoclonal antibodies are targeted to surface markers and receptors on the cell surface. For advanced lung cancer patients with driver gene negativity, small molecule inhibitor resistance, cancer immunotherapy and targeted therapy are indispensable choices.

The main targets of the monoclonal antibody medicine for the current targeted treatment of solid tumors are VEGF, EGFR, epCAM, CEACAM and the like, wherein the total survival time (OS) of the monoclonal antibody Necitumumab of the anti-EGFR target approved to be marketed in 2015 is only increased by 1.6 months, and the EGFR is widely expressed in normal tissues and has the risk of fatal blood clotting. This suggests that we need to find specific tumor antigens that can be recognized and identified.

Tumor antigens can be classified into tumor-associated antigens TAA and tumor-specific antigens TSA according to tumor antigen-specific classification. Tumor Specific Antigen (TSA) "is expressed only" in tumor cells, but not in any normal cells at different stages of development, and is an antigen produced by the accumulation of cancer cell gene mutations (e.g., kras mutation), highly individual-specific; tumor associated antigens (Tumor-associated antigen, TAA) are present in small amounts in normal cells and are highly expressed in Tumor cells (CD 19, CD20, CD38, her 2). The selection of a target point in immunotherapy is important, and an antigen which is highly expressed in tumors and is not expressed in normal tissues is usually selected as the target point, so that the toxic and side effects of the drug on normal tissues and organs are avoided.

Delta-like classical Notch ligand 3 (Delta like canonical Notch ligand, DLL 3) is a single transmembrane glycoprotein that is specifically overexpressed in tumor tissue and underexpressed or even unexpressed in normal tissue, belonging to the DSL (Delta, duration, lag-2) protein family members. The human DLL3 gene was located at 19q13 and its open reading frame length was about 1 800bp. Two transcriptional variants encoding different subtypes have been identified as the gene. As a ligand of Notch signaling pathway, it plays a role in inhibiting or promoting cancer in various tumors, and participates in the development and progression of tumors. DLL3 is a single-chain transmembrane protein that encodes 618 amino acids in length. It is highly conserved during evolution, and the proteins encoded by the human and murine DLL3 genes have 82% homologous sequences. The extracellular segment of DLL3 contains 6 epidermal growth factor (epidermal growth factor, EGF) -like repeats necessary for binding to Notch receptors, and 1 conserved DSL (Delta, serrate, lag 2) domain consisting of 40 amino acids (UniProt/Swiss-Prot Q9NYJ 7). There are 5 DSL ligands in the mammal, delta-like Notch ligand 1 (DLL 1), DLL3, DLL4, jagged1 (JAG 1) and Jagged 2 (JAG 2). Of these, DLL3 is the most inconsistent in structure. In recent years, many studies have shown that Notch signaling pathways are closely associated with the onset of small cell lung cancer. Among them, DLI3 (DeltaLike 3) as one of Notch ligands, possibly associated with a neuroendocrine phenotype, promotes the occurrence of small cell lung cancer by participating in Notch signaling pathways. Studies have shown that DLL3 protein can be detected in small cell lung cancer and large cell neuroendocrine tumor tissues, but is not expressed in normal lung tissues and tissues, so that DLL3 is hopefully a potential target for treating lung cancer.

More and more researchers focus on the preparation of antibodies, which can achieve the purpose of disease control by competitively binding with target proteins and blocking and interfering with signal paths, or can induce therapeutic effects by using antibody-specific mediated ADCC (advanced charge-coupled device) and CDC (compact-state) effects. At present, the hybridoma antibody technology is perfect, and a plurality of mouse monoclonal antibody medicines are applied to clinic, but the mouse monoclonal antibody medicines have immunogenicity, so that the development prospect is greatly limited.

With the progress of DNA recombination technology and elucidation of antibody gene structure, genetically engineered antibody technology has been widely used, and phage display technology is one of the important ones. Phage display technology can insert the DNA sequence of fully human protein or polypeptide into the proper position of phage coat protein structure gene to make the fully human gene expressed with the expression of coat protein, and at the same time, the fully human protein is displayed on the surface of phage with the reassembly of phage. The technology does not need to generate antibodies through animal immunization, truly realizes the dream of antibody full humanization, and simultaneously, the screened antibodies have low immunogenicity; easy to pass through the vessel wall, penetrate through solid tumor, etc. Furthermore, phage display technology links the genotype and phenotype of the antibody, and the screening period is short, which is an ideal mode for screening the antibody at present.

As mentioned above, ADC drugs targeting DLL3 have been entering a clinical research phase, however research into Chimeric Antigen Receptor (CAR) modified immune cells targeting DLL3 is still in the fumbling phase, as three challenges exist in treating solid tumors with CAR-T: firstly, it is required to find a tumor-specific antigen which is not expressed or is expressed in a normal tissue, secondly, the high heterogeneity of the solid tumor and the high complexity of the immune microenvironment of the solid tumor limit a plurality of therapeutic means of the solid tumor, and thirdly, the therapeutic drugs are difficult to enter the tumor tissue.

Disclosure of Invention

To explore CAR-T for the treatment of solid tumors, the present invention provides an anti-DLL 3scFv capable of specifically binding to DLL3;

the amino acid sequence of the CDR of the heavy chain in the anti-DLL 3scFv comprises CDR1 shown as SEQ ID NO.15, CDR2 shown as SEQ ID NO.16 and CDR3 shown as SEQ ID NO. 17; the CDR amino acid sequence of the light chain in the anti-DLL 3scFv comprises CDR1 shown as SEQ ID NO.18, CDR2 shown as SEQ ID NO.19 and CDR3 shown as SEQ ID NO. 20;

or,

the CDR amino acid sequence of the heavy chain in the anti-DLL 3scFv comprises CDR1 shown as SEQ ID NO.21, CDR2 shown as SEQ ID NO.22 and CDR3 shown as SEQ ID NO. 23; the CDR amino acid sequence of the light chain in the anti-DLL 3scFv comprises CDR1 shown as SEQ ID NO.24, CDR2 shown as SEQ ID NO.25 and CDR3 shown as SEQ ID NO. 26.

In some embodiments, the anti-DLL 3 scFv comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region and the light chain variable region are linked by a flexible linker;

the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.11, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 12;

or,

the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.13, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 14.

In some embodiments, the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.7 and the nucleotide sequence of the light chain variable region is shown as SEQ ID NO. 8;

or alternatively

The nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.9, and the nucleotide sequence of the light chain variable region is shown as SEQ ID NO. 10.

In some embodiments, the amino acid sequence of the anti-DLL 3 scFv is set forth in SEQ ID No. 4;

or,

as shown in SEQ ID NO. 5.

The invention also provides a nucleic acid molecule whose nucleotide sequence encodes the amino acid sequence of the anti-DLL 3 scFv according to claim 4; the nucleotide sequence is shown as SEQ ID NO.1 or SEQ ID NO. 2.

Nucleotide sequence

The invention also provides an anti-DLL 3 CAR, which has the structure of CD8 leader-DLL3 scFv-CD8 Hinge-CD8 TM-costimulatory domain-intracellular signal peptide, and comprises a CD8 leader membrane receptor signal peptide, a single-chain variable fragment as claimed in claim 1, a CD8 Hinge chimeric receptor Hinge region, a CD8 TM chimeric receptor transmembrane region, a costimulatory domain and an intracellular signal peptide which are sequentially connected in series; the costimulatory domain is 4-1BB; the intracellular signal peptide is CD3 zeta,

the anti-DLL 3 CAR objective plasmid comprises a lentiviral skeleton vector sequence and a CAR part, and the amino acid sequence comprises the following components:

1) The amino acid sequence of the CD8 leader is SEQ ID NO.50;

2) The amino acid sequence of CD8 finger is SEQ ID NO.51;

3) The amino acid sequence of the CD8 TM transmembrane region is SEQ ID NO.52;

4) 41BB co-stimulatory domain amino acid sequence is SEQ ID NO.53;

5) The CD3 zeta amino acid sequence is SEQ ID NO.54;

the anti-DLL 3 CAR related element nucleotide sequence corresponds to the amino acid sequence;

the method comprises the following steps:

1) The nucleotide sequence of the CD8 leader is SEQ ID NO.35;

2) The nucleotide sequence of CD8 finger is SEQ ID NO.36;

3) The nucleotide sequence of the CD8 TM transmembrane region is SEQ ID NO.37;

4) 41BB co-stimulatory domain nucleotide sequence is SEQ ID NO.38;

5) The nucleotide sequence of CD3 zeta is SEQ ID NO.39;

the present invention also provides a plasmid comprising a nucleotide sequence encoding a heavy chain variable region and a nucleotide sequence encoding a light chain variable region of a DLL3 scFv as described above.

The invention also provides a recombinant lentiviral vector comprising a nucleotide sequence encoding a heavy chain variable region and a nucleotide sequence encoding a light chain variable region of a DLL3 scFv as described above.

The invention also provides a cell having modified thereon a chimeric antigen receptor which is an anti-DLL 3 CAR as described above.

The invention also provides the use of an anti-DLL 3 scFv as described above, or a nucleic acid molecule as described above, or an anti-DLL 3 CAR as described above, or a plasmid as described above, or a recombinant lentiviral vector as described above, or a cell as described above, in the manufacture of an anti-tumor medicament, the tumor being small cell lung cancer.

As used herein, phage display is the cloning of a fragment of a gene encoding a polypeptide or protein into the appropriate position of the structural gene of the coat protein of a phage to form the correct reading frame, allowing fusion expression of the exogenous polypeptide or protein with the coat protein, and currently there are expression systems for coat proteins PII and PVI, etc. The fusion protein is displayed on the surface of phage, and the antibody molecule part can form independent space structure and antigen specific recognition and combination. After the target antigen and the phage antibody library are interacted for a period of time, unbound free phage is washed away, the screened phage is used for next screening after being infected with host cells, and phage specifically bound with target molecules can be enriched after multiple adsorption-elution-amplification. The technology has the greatest advantages that the genotype and the phenotype are directly connected, the genotype of the antibody can be known while the target antibody protein is obtained through screening, and the application of downstream genetic engineering technologies such as purification and the like is facilitated. Meanwhile, monoclonal antibodies, especially fully human antibodies, obtained by phage display technology reduce the immunogenicity of the antibodies and have better application value than murine monoclonal antibodies.

As used herein, the term "recombinant protein" refers to a protein that is designed/constructed artificially, rather than a naturally occurring protein. The term "recombinant" in the "recombinant protein" of the present invention does not represent a production manner thereof, and is merely used to indicate that the "recombinant protein" does not naturally exist. The recombinant protein of the invention may be an expressed protein, and may be an assembled protein.

As used herein, the term "Fc region" (fragment crystallizable, fc) consists of IgG constant region CH2, CH3 domains and hinge regions.

As used herein, the terms "treatment," "therapy," and "treatment" are used interchangeably. The term "treating" includes controlling the progression of a disease, disorder, condition and associated symptoms, preferably reducing the impact of a disease, disorder, condition or alleviating one or more symptoms of a disease, disorder, condition. This term includes curing the disease or eliminating the symptoms entirely. This term includes relief from symptoms. The term also includes, but is not limited to, non-curative palliative treatment. The term "treating" includes administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising a recombinant protein or fusion protein of the invention to prevent or delay, reduce or ameliorate the progression of a disease, disorder, condition or the effect of one or more symptoms of a disease, disorder, condition.

The information represented by the base and amino acid sequences referred to by the invention is shown in the table below, and the detailed sequences are shown in the nucleotide and amino acid sequence table in the specification.

TABLE 1 scFv antibody nucleotide sequences of 2 Positive clones obtained by phage display screening

TABLE 2 scFv antibody amino acid sequences of 2 Positive clones obtained by phage display screening

Sequence numbering	Amino acid sequence name
		SEQ ID NO.4	A7-scFv
SEQ ID NO.5	G8-scFv
		SEQ ID NO.6	Linker

TABLE 3 heavy and light chain nucleotide sequences of 2 positive clones obtained by phage display screening

Sequence numbering	Nucleotide sequence name
		SEQ ID NO.7	A7-VH
SEQ ID NO.8	A7-VL
		SEQ ID NO.9	G8-VH
SEQ ID NO.10	G8-VL

TABLE 4 heavy and light chain amino acid sequences of 2 positive clones obtained by phage display screening

TABLE 5 Complementarity Determining Region (CDR) sequences in anti-DLL3 scFv heavy chain light chain

TABLE 6 PUTAM003 expression vector sequences

Sequence numbering	Amino acid sequence name
		SEQ ID NO.27	PUT AM003 vector sequence

TABLE 7 anti-DLL3 CART nucleotide sequence (containing lentiviral backbone)

TABLE 8 anti-DLL3 CART amino acid sequence

The technical scheme of the invention has the following advantages: the invention screens two fully human scFv antibodies targeting DLL3 by phage display technology. The invention takes the extracellular section of DLL3 as antigen, 2 fully human anti-DLL3 scFv (single chain variable fragment) are enriched and screened by phage display technology, and the invention is not subjected to artificial immunization, belongs to fully human natural phage antibody, and lays a foundation for developing fully human DLL3 antibody and later-stage DLL3 antibody to clinical development; 2 fully human anti-DLL3 scFv obtained by screening were identified by Elisa and flow cytometry as being capable of specific binding to DLL3 antigen.

The invention verifies the specific killing of the anti-DLL 3 CAR-T on the DLL3 positive tumor cells and the cytokine secretion of the anti-DLL 3 CAR-T after the target cells are stimulated; lays a foundation for developing the full-human DLL3 antibody and the later-stage DLL3 antibody to clinical development.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.

FIG. 1 is an enrichment screen of phage antibody libraries.

FIG. 2 phase Elisa identifies the specific binding activity of monoclonal phage to the extracellular domain of DLL 3.

FIG. 3 prokaryotic expression of anti-DLL 3 soluble antibody A7G 8, the binding ability to antigen was identified.

FIG. 4 PCR amplified A7G 8scFv fragment electropherograms.

FIG. 5 vector fragment of the PUTAM003 vector BspEI and EcoRV after cleavage.

FIG. 6 demonstrates the binding of A7 scFv-hFc, G8scFv-hFc recombinant proteins to antigen.

FIG. 7 is a graph of FIG. 7 flow cytometry detecting specific binding of A7 scFv-hFc and G8scFv-hFc to small cell lung cancer cell line SHP-77.

FIG. 8 DLL3 CART structure

FIG. 9 transduction efficiencies of D14, anti-DLL3 and anti-CD19 CART after lentivirus transduction.

FIG. 10 LDH killing level of anti-DLL3 and anti-CD19 CART

FIG. 11 detection of cytokine levels released by effector cells anti-DLL3-CART and anti-CD19 CART after co-incubation with target cells SHP-77.

Detailed Description

In order to facilitate an understanding of the invention, reference will now be made to certain embodiments and specific language will be used to describe the same. However, it should be understood that these specific embodiments are not intended to limit the scope of the invention. Any alterations and further modifications in the described embodiments, and any further applications of the invention, are contemplated as would normally occur to one skilled in the art.

Example 1

Screening of anti-DLL3 phage antibody scFv

The phage antibody library is formed by amplifying antibody heavy chain variable region (VH) and light chain variable region (VL) genes from healthy human B lymphocytes by using a PCR technology, and expressing scFv segments on the surface of phage. The fully human scFv phage antibody library is from Shanghai you-Kadi biological medicine company, and DLL3 antibodies are screened from the fully human scFv antibody library by using phage display technology; his-DLL3 extracellular region protein: human DLL3 Protein, his Tag (MALS verify), accession number DL3-H52H4-100ug, purchased from ACRO, for screening of anti-DLL3 specific antibodies; coli Tg1 (E.coli Tg1, from the manufacturer Lucigen, cat# 60502-2); pancreatin (trypsin, cat# and spec T1426-250 mg) was purchased from Sigma-Aldrich;

His-DLL3 extracellular domain protein is coated in an ELISA plate, and after the phage antibody library is incubated with a target protein molecule (His-DLL 3 extracellular domain protein), unbound free phage is washed away, and the bound and adsorbed phage is digested with pancreatin. And (3) continuing to infect the phage eluted by pancreatin digestion to obtain E.coli Tg1 for amplification, so as to carry out the next round of screening.

Results: adsorption of human scFv phage antibody library with His-DLL3 extracellular region protein as solid antigen for 4 roundsUpon elution and amplification, enrichment and screening, the input/output (output/input) ratio of phage was continuously increased, and phage antibody yield was increased from round 1, 0.14x10 ^-7 128.75x10 to round 4 ^-7 1019.27-fold improvement (see FIG. 1), phage specifically binding to the target protein are highly enriched.

Example 2

Identification of Activity of anti-DLL 3 phages by Phage enzyme-Linked immunization (Phage elisa)

His-DLL3 extracellular protein sources were the same as in example 1; 96-well plates (cat No. 3590) were purchased from Costar corporation; mouse Anti-M13 Anti-body (HRP) (cat. No. S004H-250 uL) was purchased from Chengdu Apac; m13KO7 Helper phase (N0315S) was purchased from NEB.2XYT culture medium formula comprises tryptone 16g/L, yeast powder 10g/L, and sodium chloride 5g/L; placing part of double distilled water in a beaker, weighing and pouring the peptone, the yeast powder and the sodium chloride in the proportion, stirring until the peptone, the yeast powder and the sodium chloride are dissolved repeatedly, and clearing. The weighed agar powder is put into a conical flask, the culture solution is poured into the conical flask, and the sealing film is sealed and sterilized for 20 minutes by an autoclave at 121 ℃. The corresponding antibiotic is added after cooling to below 55 ℃.

2XYTA agar culture plate, tryptone 10g/L, yeast powder 5g/L, sodium chloride 8g/L, agar powder 15g/L. Pouring the solid culture medium into a flat plate, placing part of double distilled water in a beaker, weighing and pouring the peptone, the yeast powder and the sodium chloride in the proportion, stirring until the peptone, the yeast powder and the sodium chloride are dissolved repeatedly, and clearing. Placing the weighed agar powder into a conical flask, pouring the culture solution, sealing by a sealing film, and sterilizing by high-pressure steam. The high pressure steam sterilization is cooled to about 55 deg.C (hand back tolerance) and then antibiotic is added to avoid deactivation of antibiotic by too high temperature. According to the following steps of 1: ampicillin was added at a ratio of 1000, such as 400ml medium plus 400. Mu.l ampicillin. Too high a temperature may result in reduced or deactivated antibiotic activity, with most antibiotics not withstanding high temperatures. When the plates are poured, air bubbles are avoided, and a plurality of plates are stacked together so as to prevent excessive water drops from being condensed due to too cold plate covers. After the agar has completely solidified, it is inverted and left at room temperature for one day to avoid premature storage at 4 ℃ (after incubation at 37 ℃ earlier, bacterial colonies are fused by water droplets) and placed in an ultra clean bench overnight and then returned to the refrigerator, taking care of sterility of the refrigerator. Marking is done

From the bacterial colonies obtained after the last round (round 4) of screening, 96 clones were randomly selected, amplified and Phage supernatant was identified by Phage ELISA for affinity to His-DLL3 extracellular region protein. The Output phage antibody library obtained by the 4 th round of screening is subjected to gradient dilution (10) ² Multiple dilution, 10 ⁴ Multiple dilution, 10 ⁶ Multiple dilution, 10 ⁷ Multiple dilution, 10 ⁸ Dilution), 200ul of log-phase Ecoli.Tg1, 2YTA plates (ampicillin 100 mg/ml) were applied and incubated overnight at 37 ℃.2 96 deep well plates, 300ul 2YTAG (1% glucose, 100mg/ml ampicillin) were added to each well, 60ml 2YTAG was prepared, 92 clones were randomly picked from the plates of the last round of screening and added to deep well plates, the remaining 2 TG1 controls (i.e.blank E.coli controls) and 2 YTAs controls (i.e.blank medium controls), gun blow, shaking at 37℃for 3.5-4h. Culturing in 96-well cell culture plate, collecting 100ul of bacteria from 96 deep well plate, adding 100ul of 50% glycerol for culturing, and storing at-20deg.C. Adding 50ul of Helper phase into 3.3ml of 2YT antibiotic-free culture medium, mixing, adding 30ul of culture medium with Helper phase into each well of a deep well plate, extending to the position below the liquid surface, and mixing. Incubators were left at 37 degrees celsius for 30 minutes. 220 rpm at 37 degrees celsius for 1 hour. The well plates were supplemented with 400ul 2YT AMP+KANA + medium (ampicillin double antibody) per well and incubated overnight at 30℃at 220r per final volume 600ul per well. Antigen coating, antigen DLL3-His 96-well Elisa plate, BSA 96-well Elisa plate (detection of nonspecific binding), 1ug/ml,4 degrees overnight. Phage Elisa identification step 1) the next day, taking out the 96 deep-hole plate of the culture phase, standing, precipitating thalli, and taking out the supernatant. 2) Antigen coated 96 well Elisa plates were incubated overnight at 4 degrees celsius, each well was blocked with 200ul of 2% skim milk, 1h, and pbst washed 3 times. 3) During the period of the Elisa plate milk sealing, 120ul of Phage supernatant and 120ul of 2% skimmed milk are taken, the Phage supernatant is sealed by a dilution plate, the corresponding supernatant is added as a primary antibody after the sealing is finished, the depth pore plate corresponds to the supernatant added by the 96-hole Elisa plate one by one, 100 ul/hole is incubated for 1.5h, and PBST is washed for 6 times. 4) anti-M13-HRP (anti-M13 phage) was added and diluted 1:5000 with 2% skim milk, 100 ul/well and incubated for 1h. 5) TMB 100 ul/well, developed for 10 min. 6) 2M H2SO4 100 ul/well, stop color development, and the reading OD450nm of the ELISA reader, with the negative standard OD450 <0.2. 7) Positive clones shown by Phage Elisa results are selected and sent to the biological company Limited for sequencing, and the diversity of positive clone sequences is identified.

As a result, 61 positive clones specifically binding to DLL3 were detected by phage Elisa (FIG. 2), and identified as 2 sequences by sequencing by biological engineering, respectively: the anti-DLL 3 positive clone A7 and the anti-DLL 3 positive clone G8 are identified by biological sequencing, the obtained scFv nucleotide sequences are shown in table 1, the scFv amino acid sequences are shown in table 2, the heavy chain and light chain nucleotide sequences are shown in table 3, the heavy chain and light chain amino acid sequences are shown in table 4, and the heavy chain and light chain Complementarity Determining Region (CDR) amino acid sequences are shown in table 5.

Example 3

Prokaryotic expression and preliminary activity identification of anti-DLL 3 scFv

Plasmid DNA miniprep kit was purchased from corning; coli Rosetta competence was purchased from tiangen biochemical technologies limited; HRP-labeled anti-c-myc antibodies were purchased from Bethy; TMB was purchased from eBioscience.

1. Extraction and purification of A7G 8 Tg1 monoclonal plasmid: A7G 8 monoclonal strain identified by Phage elisa as specifically binding was used to store glycerol bacteria (50% glycerol to bacterial solution ratio 1 to 1). 20ul of the stored positive clone glycerol bacteria were cultured overnight in 5ml 2YTA medium (Ecoli. Tg 1) at 220r,37 ℃. 1-4ml of the bacterial liquid overnight in 2YTA medium, 12000g,1min, the supernatant was discarded, and the filtrate was blotted with filter paper. 250 μl Buffer S1 is added, and the mixture is blown and mixed uniformly, and the mixture is suspended uniformly and can not be agglomerated. Adding 250 μl Buffer S2, gently (preventing genome DNA fragmentation) and fully turning over 4-6 times, mixing well to allow bacterial cells to fully lyse until clear solution is formed. Add 350. Mu.l Buffer S3 and mix well with shaking. Preventing local over-concentration, changing into linear and ring-opening structure, mixing for 6-8 times, 12000g,1min, retaining supernatant, and discarding protein flocculent precipitate. The supernatant was pipetted into a centrifuge column (as in a 2ml centrifuge tube), 12000g,1min;500 μl Buffer W1, 12000g,1min, and discarding the filtrate; 700. Mu.l Buffer W2, 12000g,1min, discarding the filtrate, 700. Mu.l Buffer W2, 12000g,1min, discarding the filtrate; idle, 12000g,1min, discard filtrate (5 min with ultra clean bench blow, remove ethanol); spin column was transferred to a fresh 1.5ml EP tube, and 60-80. Mu.l of Eluent or deionized water (eluted without the cationic DNA being able to bind to the Silica by mutual repulsion) was added to the center of the membrane, and allowed to stand for 2 minutes (DNA dissolution) 12000g,1min. The elution efficiency is improved by heating Eluent or ddH20 (double distilled H O) to 65 ℃ in advance. Double stranded DNA concentration was measured using a Nano drop, and the concentration and A260/280 were recorded. 10ul of plasmid was taken and sent to the biological Co.Ltd for sequencing.

2. Sequencing to identify scFv sequence correctly, and then converting the scFv sequence into Ecoli. 1) The competence of Rosetta (DE 3) was removed from-80 and placed rapidly on ice at 4℃and the transformation efficiency of the plasmid was affected at ambient temperature. 2) 200ng of the above extracted, correctly sequenced plasmid was added per 50ul of Rosetta (DE 3), gently mixed and allowed to stand on ice at 4℃for 30 minutes. 3) Heat activated, 42 degrees celsius, 60 seconds, remove and place on ice for 2 minutes, add 700 microliters of sterile 2YT medium without antibiotic, mix well. 4) Shake culturing at 37deg.C for 1 hr (220 rpm), and plating. 5) The bacterial liquid transferred into the plasmid was taken out and centrifuged at 3500rpm for 5 minutes in order to increase the bacterial concentration. 6) After centrifugation, a portion of the supernatant was aspirated, the total system 750 was aspirated, 490 μl of supernatant was discarded, and the remaining liquid was mixed with a 200 μl gun to increase conversion concentration. 7) 200 microliter of the bacterial liquid was pipetted into a 2YT agar medium plate containing ampicillin to distribute it evenly. The mixture was allowed to stand at 37℃until the liquid was absorbed, and then the mixture was allowed to stand in an incubator at 37℃overnight. 8) The following day 3 single clones were selected for sequencing by bioengineering.

3. IPTG-induced expression of soluble antibodies: 1) 30ul of the glycerol bacteria of the A7G 8 monoclonal with correct sequence are transferred to 3ml-2YTA culture based on a bacterial culture tube, and 50% glycerol is preserved after shaking overnight at 37 ℃. 2) According to the following steps of 1:100 transfer shaking for night bacteria expansion culture, adding 10ml of ampicillin resistant culture medium into 100ul, observing culture for 3-3.5 h, and inducing after logarithmic growth phase (OD 450 nm=0.4-0.5). 3) Centrifugation, removal of supernatant, replacement of medium, addition of 100ul of IPTG (concentration 0.1m according to 1: 100) and 10ul of ampicillin (1: 1000 Resuspension of the cells, 30 ℃,220rpm overnight induction of expression. 4) Periplasmic protein was extracted (on 4 degree ice): the expressed bacterial liquid was induced overnight and centrifuged at 3500,4 ℃for 10 minutes. 5) Add 1ml of TES buffer with lysozyme (lysozyme should be freshly prepared on ice, add 1mg/ml lysozyme on ice), re-suspend and place on ice for 0.5h. The bacterial solution was allowed to stand on ice for 1 hour after lysozyme was added to the bacterial solution, so that the protein was stabilized. 6) Centrifugation was performed at 3500,4 ℃for 10 min, and the supernatant containing the periprotein was transferred to a 2ml centrifuge tube, labeled and stored in a-20℃refrigerator for periprotein ELASA.

4. Peripherin protein Elisa identified antibody affinity to DLL3 antigen: DLL3-His antigen was coated at a concentration of 1ug/ml on a 96 well Elisa plate, sealed membrane plate, and overnight at 4 ℃. After antigen-coated Elisa plates overnight, 0.05% pbst was washed once, 2% skim milk was blocked for 1h, during which time 2% skim milk was used for weeks to protein. After the end of the Elisa plate closure, primary antibody was added at 100 ul/well and incubation was completed for 1 hour. Wash 3 times with 0.05% pbst. 2% skim milk was used at 1:1000 proportion of HRP-labeled anti-c-myc secondary antibody, 100 ul/well, was added and incubated for 1h. Wash 3 times with 0.05% pbst. 100 ul/well TMB color development was added to 100ul, and the color development was continued for 10 minutes, and the color was terminated too deeply. The color reaction was stopped with 100ul of sulfuric acid (2M) per well. The enzyme-labeled instrument performs photometric measurement (450 nm).

Results: after extracting the A7G 8 plasmid, converting the E.coli Rosetta competent, amplifying and culturing after sequencing and identifying the correct sequence, inducing the soluble antibody to be expressed by the prokaryote through IPTG, extracting the E.coli Rosetta week to protein, and then carrying out week to protein Elisa to identify the binding activity. The peripherin Elisa results showed that both scFv A7 and G8 could specifically bind to DLL3 antigen (fig. 3), and the purpose of the Elisa plate coating BSA (bovine serum albumin) and IgG (immunoglobulin) was to see if specific binding of anti-DLL 3 antibody (A7G 8) could occur. The results show (fig. 3) that anti-DLL 3 scFvA 7G 8 can specifically bind to DLL3 antigen without non-specific binding (without binding to unrelated antigens such as BSA).

Example 4

Construction of anti-DLL 3 Single chain antibody (scFv-hFc)

Seamless cloning kit was purchased from nuuzan; primestar DNA polymerase from TAKARA; the PUTAM003 expression vector (Ukadi biosis Co., ltd., see Table 6 for sequence); TOP10 competence was purchased from Tiangen biology Co.

In the invention, we also constructed recombinant single chain antibodies against DLL3, using seamless cloning to fuse the scFv fragment of A7G 8 with the IgG Fc fragment. The plasmids A7 and G8 extracted in example 3 were used to design the following primers for PCR amplification:

A7-F(SEQ ID NO.58)：accggcgtgcactccgatatcCAGGTTCAGCTGGTGCAGTCT。

A7-R(SEQ ID NO.59)：tgtgtgagttttgtctccggaTTTGATCTCCACCTTGGTCCC。

G8-F(SEQ ID NO.60)：accggcgtgcactccgatatcCAGGTACAGCTGCAGCAGTCAG。

G8-R(SEQ ID NO.61)：tgtgtgagttttgtctccggaTAGGACGGTCAGCTTGGTCCC。

PCR reaction amplification system: 100ng of the plasmid of interest, 2ul of F sense primer and 2ul,PrimeStar 25ul,ddH2O to 50ul of R antisense primer. PCR reaction conditions: pre-denaturation at 98℃for 2min, denaturation at 98℃for 10 sec, annealing at 55℃for 10 sec, extension at 72℃for 15S, (denaturation-annealing-extension 35 cycle), extension at 72℃for 5min. The scFv segments of A7 and G8 are obtained by amplification, the nucleotide sequences are shown in table 1, and the electrophoresis diagram is shown in figure 4. And (3) recovering PCR products by using glue, and recovering scFv segments obtained by PCR amplification. Electrophoresis and glue recovery: a) 1% Agarose gel, 25ml-TAE,0.25g-Agarose, and microwave oven heated for 90s to ensure complete dissolution of the Agarose; b) Taking out PCR products from a PCR instrument, adding 5.5ul loading buffer (10X) to each antisense system in 50ul of the whole system, adding 10ul of D15000+2000 (Tiangen) markers to the first hole, and then sequentially loading samples; c) And (3) replacing a new electrophoresis liquid, and performing constant-pressure running electrophoresis after the gel is not coated, wherein the voltage is regulated to 120 v. d) The indicator was run to the 2/3 position to turn off electrophoresis, prevent run through loss of DNA, the digital gel image processing system tan 2500 photographed, and the marker was compared to find the expected band. e) Cutting, recovering, loading into EP tube, peeling, weighing, adding 200ul NTI per 100mg, and thawing at 50deg.C for 10 min. f) Transfer to a purified silica gel column, centrifuge, 11000g,30s, discard supernatant. g) 700ul of NT3 was added and washed twice, centrifuged for 11000, 30s, and the supernatant was discarded. h) Idling 11000g,1min, placing in a 65 ℃ water bath kettle for 5min, and volatilizing NT3. The sterilized water is preheated to 65 ℃ in advance. i) Transfer to a 1.5ml EP tube, add 50ul of ddH2O to the center of the membrane, rest for 2min, centrifuge 11000g for 1min, transfer to a new 1.5EP tube after centrifugation, and Nano drop to determine the recovered product concentration. Mammalian cell expression vector PUTAM003 containing the human IgG1 Fc fragment was derived from eucadi biopharmaceutical, and the partial sequences are shown in table 6. The PUTAM003 vector was subjected to enzyme digestion using both BspEI and EcoRV. Carrier enzyme cutting system: PUTAM003 10ug,BspEI 10ul,EcoRV 10ul,Cutsmart Buffer (10X) 20ul, enzyme free water to 200ul, water bath at 37℃for 30 minutes. After digestion, the digested product is subjected to agarose gel electrophoresis, and the digested carrier fragment is recovered by referring to the previous step, and the electrophoresis diagram of the digested product is shown in FIG. 5. Performing seamless cloning homologous recombination, and cloning the obtained scFv segment by PCR amplification into a PUTAM003 expression vector. Preparing a reaction system on ice: vector 140ng, insert 14.4ng,5 XCE II Buffer 4ul,Exnase II 2ul, enzyme free water to 20ul. Reaction conditions: placing on ice for 5min at 37 ℃ after connection is finished, standing for 5min, converting 5ul of connection product into 50ul of TOP10 competent, standing for 30min on ice, thermally activating for 60s at 42 ℃, standing for 2min on ice, adding 700ul of nonresistant 2YT culture medium, performing shake culture for 60min at 37 ℃,3000g, centrifuging for 5min, discarding 400ul of supernatant, uniformly blowing the rest 200ul, coating a flat plate, uniformly distributing the flat plate by using a coating rod, inverting the flat plate, and culturing overnight. 3 single clones were picked per plate and sequenced in the biological engineering.

Results: designing primers, amplifying scFv segment sequences of A7 and G8 by PCR, and performing agarose gel electrophoresis, wherein the result is shown in FIG. 4, and the scFv segment size is consistent with the expected size; the PUTAM003 expression vector was digested with BspEI and EcoRV, and agarose gel electrophoresis showed that the digested fragment size was consistent with that expected (fig. 5). After homologous recombination of the scFv segment and the vector after enzyme digestion, sequencing and identification of the recombinant monoclonal of A7 scFv-hFc and G8 scFv-hFc are correct by the biological company.

Example 5

Eukaryotic expression of anti-DLL 3 single chain antibodies and further characterization of Activity (Elisa, streaming)

The extraction kit of Endotoxin-free plasmid DNA purification is available from MACHEREY-NAGEL;

DMEM was purchased from Gibco; mouse anti-human IgG-Fc (HRP) was purchased from Bethyl; PE anti-human Fc antibody was purchased from Biolegend;293T cells were purchased from ATCC and SHP-77 small cell lung cancer cell line from Shanghai Proc.

1. Large numbers of plasmids are required for large numbers of transfection, thus the present inventionThe invention uses Endotoxin-free plasmid middling kit, endotoxin-free plasmid DNA purification to extract a large amount of plasmids, and the steps are as follows 1) after amplifying and culturing TOP10 monoclonal bacteria with correct sequence A7 and G8 according to 1:100 was inoculated into 200ml of 2YTA medium, 220r,37℃and cultured overnight. 2) Bacterial liquid was collected from the Erlenmeyer flask and centrifuged at 8000g,4℃for 15min, and the supernatant was discarded. 3) Adding solution I (suspension), buffer RES-EF 8mL, shaking, and mixing to disperse the bacterial solution without agglomerating. 4) Adding 8ml of solution II and Buffer LYS-EF (lysate with blue indicator), and gently turning over and mixing (preventing genome DNA fragmentation); completed within 5 minutes at room temperature. 5) 2 centrifugal columns are sleeved with white discs and put on a 200ml conical flask which is used for receiving liquid leakage and is rinsed by 15ml Buffer EQU-EF

An Xtra column, a equilibration column and a filtration membrane. Note that the addition along the sides of the post does not face the hole. 6) Adding solution III (neutralization solution), adding 8ml per Buffer NEU-EF tube, mixing, and standing upside down to make blue disappear and white flocculent precipitate appear. Standing on ice for 5min. Centrifuge 6000g,1min. 7) Transferring the supernatant to +.>

5ml buffer FIL-EF was added to the Xtra column, and the paper film was discarded after the leakage was completed. 8) 35ml Buffer ENDO-EF was added. 9) After the Buffer ENDO-EF is leaked, 15ml Buffer WASH-EF is added. This step is completed and the centrifuge tube needs to be replaced with a new one. 10 5ml Elution buffer ELU-EF, eluting (fresh centrifuge tube). 11 After the elution was completed, 3.5ml of isopropyl alcohol was added, the plasmid was precipitated, the mixture was left to stand at-20℃for 20 minutes, centrifuged at 12000rpm at 4℃for 10 minutes, and the supernatant was discarded and the mixture was dried by reverse-buckling on a three-fold paper (at this time, the plasmid was on the wall and care was taken not to be poured off). 12 Washing and drying with 2ml of 70% EtOH ethanol, 12000g, centrifuging at room temperature for 5min, discarding supernatant, 12000g,1min, sucking out residual ethanol, and air drying at room temperature for 10-15min.13 After the precipitate is dried in the air and becomes transparent, adding 800ul of TE-EF into the precipitate to dissolve and mix uniformly, and detecting the DNA concentration by using NANO DROP. Taking 5ul of the plasmid sequences extracted from the biological engineering sequencing and identification of the plasmid sequences.

2. Eukaryotic expression of single chain antibody plasmid was transfected into 293T by calcium chloride as follows: 1) The A7 scFv-hFc and G8 scFv-hFc recombinant plasmids with correct sequencing are prepared according to the following steps of 1:1 proportion of cotransfection 293T cells, 293 cells 1x107 cells/dish, 80% cell confluence, medium exchange (DMEM+4% FBS) before transfection, plasmid 22 ug/dish, total volume of water, calcium chloride, plasmid 500 ul/dish, HBS 500 ul/dish, 10ml cell culture solution added after shaking and fully mixing the transfection reagent, and 3 dishes 293 cells were transfected together. 2) The cells were transfected with the plasmid for 8h, then the medium (DMEM+4% FBS) was changed, 10ml of medium was supplemented every 24h, twice, and finally 30ml of culture supernatant was collected for each dish of cells, and the cells were removed by filtration through a 0.45um filter.

3. Elisa identification of antibody affinity with DLL3 antigen in 293 culture supernatant: DLL3-His antigen was coated at a concentration of 1ug/ml on a 96 well Elisa plate, sealed membrane plate, and overnight at 4 ℃. After antigen-coated Elisa plates overnight, 0.05% pbst was washed once, 2% skim milk was blocked for 1h, during which time 2% skim milk was used for weeks to protein. After the end of the Elisa plate closure, primary antibody was added at 100 ul/well and incubation was completed for 1 hour. Wash 3 times with 0.05% pbst. 2% skim milk was used at 1:1000 ratio of Mouse anti-human IgG-Fc (HRP) secondary antibody, 100 ul/well, was added and incubated for 1h. Wash 3 times with 0.05% pbst. 100 ul/well TMB color development was added to 100ul, and the color development was continued for 10 minutes, and the color was terminated too deeply. The color reaction was stopped with 100ul of sulfuric acid (2M) per well. The enzyme-labeled instrument performs photometric measurement (450 nm).

4. Flow cytometry detection of antibody binding activity to SHP-77 cell surface antigen in 293 culture supernatant: the suspension of SHP-77 cells was collected, the culture supernatant was discarded, the bottom of the dish was infiltrated with 10mL of physiological saline, the physiological saline was discarded, 1mL of pancreatin was added to each dish of cells to digest the cells, the digestion time was determined according to the cell line characteristics, the cells were observed under a microscope to be non-adherent, suspended and morphologically rounded, and 5mL of complete medium was added to terminate the digestion. Centrifuging at 1500rpm for 5min, discarding supernatant, adding 5mL of PBS respectively for resuspension, centrifuging at 1500rpm for 5min, discarding supernatant, using 1mL of complete medium for resuspension of cells, counting trypan blue, taking 2x106 cells for resuspension in 100ul of PBS, adding A7 scFv-hFc and G8scFv-hFc antibodies for uniform mixing, incubating at room temperature for 45 min, washing with PBS for one time, discarding supernatant, adding 2ul of secondary anti-PE anti-human Fc antibody, incubating at room temperature for 25 min, washing with PBS for one time, discarding supernatant, and detecting by 200 mu L of PBS. The results are shown in FIG. 7.

Results: the A7 scFv-hFc and G8scFv-hFc plasmids were transfected into 293T cells, respectively, using a calcium chloride transfection method, scFv-Fc single chain antibodies were expressed in the culture supernatants, and the supernatants were subjected to Elisa assay. FIG. 6Elisa results show that both scFv-hFc of A7 and G8 can specifically bind to DLL3 antigen (FIG. 6), and that the purpose of the Elisa plate coated BSA (bovine serum albumin) was to see if anti-DLL 3 antibody (A7G 8 cFv-hFc) did not specifically bind to non-target antigen. The results show (fig. 6) that anti-DLL 3 scFvA 7G 8 can specifically bind to DLL3 antigen and do not produce non-specific binding (do not bind to BSA). FIG. 7 flow cytometry detects specific binding of scFv to cells, and shows that both A7 scFv-hFc and G8scFv-hFc proteins can specifically bind DLL3 antigen expressed on small cell lung carcinoma cell line SHP-77, with G8scFv-hFc binding being weaker (FIG. 7), thus selecting A7 scFv for experiments following the present invention.

Example 6

Construction of anti-DLL 3 CAR and packaging of lentiviruses

The lentiviral backbone plasmid vector was PSB1819 from eucadi; both pPac-R, pPac-GP and pEnv-G are from Ubacodi; TOP10 competence was purchased from Tiangen biology Co.

The scFv fragment of the anti-DLL 3 positive clone A7 obtained by screening in example 5 was seamlessly cloned into a lentiviral backbone plasmid vector PSB1819, the lentiviral backbone plasmid vector was PSB1819, and as shown in FIG. 8, the experiment of seamless cloning and glue recovery was described in example 4, TOP10 E.coli was transformed after plasmid recombination was successful, and then the cells were expanded and extracted, and 293T cells were transfected with lentiviral backbone plasmid and lentiviral packaging plasmid pPac-R, lentiviral packaging plasmid pPac-GP and lentiviral packaging plasmid pEnv-G after plasmid extraction was completed. The packaging steps are as follows: plating the 293T cells to be transfected by using a 10cm culture dish, and replacing the culture medium with a serum-free culture medium after the cell density reaches about 70%, and carrying out a slow virus packaging step: the first step is to change the culture medium to serum-free culture mediumCaCl2 solution and a certain volume ratio of four plasmids are added into the tube, bacterial Endotoxin Test Water (BETW) is added, and HBS is added while swirling. Adding a proper amount of prepared transfection reagent into transfected cells by adding 2mL CaCl ₂ 3 packaging plasmids (13. Mu.g pPac-R, 20. Mu.g pPac-GP, 5. Mu.g pEnv-G) and 20. Mu.g plasmid of interest (anti-DLL 3 CAR), and bacterial endotoxin test water was added to 4mL]Mixing with CO under gentle shaking ₂ Wait for 6 hours in incubator and change liquid. And after 6 hours was replaced with DMEM complete medium. Collecting virus supernatant at 24 hr, 48 hr and 72 hr, preserving at 4deg.C, filtering the virus supernatant with 0.45um filter, filtering cell residue, concentrating the virus with PEG8000 (polyethylene glycol 8000), incubating at 4deg.C for 12 hr, centrifuging at 3000rpm for 15 min, centrifuging, discarding supernatant, dissolving the virus precipitate with appropriate amount of sterile PBS, packaging and preserving in-80deg.C refrigerator to obtain anti-DLL3 recombinant lentiviral vector.

Results: the construction of anti-DLL3 CAR-T cells and anti-CD 19 CAR-T cells CAR is shown in FIG. 8, the nucleotide sequences of the important elements (CD 8 leader, CD8 transmembrane domain, 41BB co-stimulatory domain, etc.) in the CAR vector are shown in Table 7, and the amino acid sequences are shown in Table 8. Lentiviral packaging was performed following the procedure described above, with CD19 CAR set as the negative CAR control in the present invention.

Example 7

Preparation and characterization of anti-DLL 3CAR-T cells

FITC-Protein L Protein was purchased from Biolegend.

CD4+CD8+ T cells were isolated from human peripheral blood mononuclear cells using CD4 and CD8 magnetic beads, placed in T25 flasks coated with CD28 antibody for 24h of activation, and after complete activation of T cells, the recombinant lentiviral vector prepared in example 2 was added at MOI=120, washed 2 times with PBS 48h after infection, resuspended in fresh complete medium, and then the transfection efficiency of lentiviral transfected T cells was examined by FITC-Protein L Protein using a flow cytometer. Protein L is an immunoglobulin-binding Protein that specifically binds to immunoglobulin light chains.

Construction of anti-DLL 3CAR-T cells and anti-CD19 CAR-T cells CARs were as shown in figure 8. After T cells were transfected with lentivirus, the infection efficiency was examined on day 14. Wherein, the T cell activation day is D0, transfection is performed 24h after activation, and the lentivirus transfection day is D1.

Results: as shown in fig. 9, the transduction efficiency of anti-DLL3 CART cells was 46.94% at day 14, and anti-CD19 CART was 61.99%.

Example 8

Detection of LDH killing level of anti-DLL 3CAR-T cells on different target cells

CytoTox 96Non-Radioactive Cytotoxicity Assay, cat No. REF: g1782, from Promega. A549 is from Shanghai national academy of sciences cell bank

Lactate Dehydrogenase (LDH) release assay detects the efficiency of killing target cells by effector T cells. The suspensions of target cells and effector cells were collected separately, centrifuged at 1500rpm for 5min, the supernatant was discarded, 3mL of PBS was added separately for resuspension, and centrifuged at 1200rpm for 5min. Effector cells and target cells were resuspended in 1mL AIM-V complete medium, respectively, and mixed well and counted using the hemocytometer method. Setting effector cells: at 2.5:1 target cells (E: T), 1X10 target cells were added per well of 96-well plate ⁴ 2.5x10 effector cells were added per well ⁴ The volume was 50ul. When E: T is set to be 5:1, 1x10 target cells are added to each well of a 96-well plate ⁴ 5X10 effector cells were added per well ⁴ The volume was 50ul. When E: T is set to be 10:1, 1x10 target cells are added to each well of a 96-well plate ⁴ Effector cells were added 1X10 per well ⁵ The volume was 50ul. The LDH killing experiment needs to be provided with three compound holes, effector cells and target cells are prepared and then spread into a 96-well plate, the 96-well plate is sealed by a sealing film and then placed into a centrifuge, 250g is put into the centrifuge, 3 g is lifted and lowered for 1 min, and the centrifuge is put into a constant temperature incubator at 37 ℃ for incubation for 24h. 10ul of lysis solution was added to each of the maximum lysis wells 45min prior to detection, incubated in a 37℃incubator for 45min, incubated for 10 min after addition of LDH substrate, and absorbance readings at 490nm were taken using an microplate reader. Only the largest lysis group of target cells requires addition of lysis solution, the other groups do not require addition of lysis solution.

Results: LDH killing results showed that compared to control non-DLL 3 target anti-CD19 CAR-T cells, anti-DLL3 CAR-T cells had higher specific killing against small cell lung cancer cell line SHP-77 that highly expressed DLL3, and had a clear dose dependence, with higher killing levels for CAR-T cell amounts, but no killing against DLL3 negative lung cancer cell line a549 at any effector cell target cell ratio (10:1, 5:1, 2.5:1) (fig. 10). The surface anti-DLL3 CART cells can specifically kill DLL3 positive tumor cells and have dose dependency.

Example 9

Cytokine secretion by anti-DLL3 CAR-T cells during killing

CBA cytokine detection kit was purchased from BD Bioscience.

Cell suspensions of target cells SHP-77 and effector cells Anti-CD19 CART and Anti-DLL3 CART were collected, respectively, centrifuged at 1500rpm for 5min, the supernatants were discarded, 3mL PBS was added, respectively, and the suspension was centrifuged at 1200rpm for 5min. Effector cells and target cells were resuspended in 1mL AIM-V complete medium, respectively, and mixed well and counted using the hemocytometer method. Setting effector cells: at a target cell (E: T) of 10:1, 1X10 target cells were added to each well of a 96-well plate ⁴ Effector cells were added 1X10 per well ⁵ The volume was 50ul. Spreading the prepared effector cells and target cells into a 96-well plate, sealing the 96-well plate by a sealing film, placing the 96-well plate into a centrifuge, centrifuging the mixture by lifting 3 and lowering 1 for 5min, and placing the mixture into a constant temperature incubator at 37 ℃ for 6h. The supernatants were collected for cytokine detection in 1.5mL EP tubes. a sample treatment: after centrifugation of the cell suspension at 1500rpm for 3min, the supernatant was collected in a fresh 1.5mL EP tube. b, preparing a standard product: and adding 2mL of standard substance diluent to dilute the standard substance freeze-dried powder, and standing for 15min at room temperature. The standard was then diluted 2-fold gradient (10 gradients total from the highest concentration to the blank dilution). c 50. Mu.L of standard or sample was added to the new EP tube, followed by 50. Mu.L of magnetic beads and 50. Mu.L of detection antibody, vortexing well, and incubation at room temperature for 3h. d washing twice by adding a Wash Buffer, discarding the supernatant, adding 200 mu L of the Wash Buffer, and re-suspending on a machine to detect the cytokine IL-2/IL-4/IL-6/IL-10/IFN-gamma/TNF. The CBA content of the supernatant was measured by performing 3 repeated experiments.

Results: cytokine secretion levels of effector cells Anti-CD19 CART and Anti-DLL3 CART were detected by flow cytometry after 6h co-incubation with target cell SHP-77, and as a result, IL-2, IFN-r and TNF-a were secreted in large amounts and small amounts were secreted by control CD19 CART cells after 6h co-incubation of Anti-DLL3 CART with DLL3 positive target cell SHP-77, as shown in FIG. 11. The CBA detection result shows that after the anti-DLL3 CART is contacted with DLL3 positive cells, a large amount of anti-tumor factors IL-2, IFN-r and TNF-a are secreted by the stimulation of antigen, so that target cells are killed.

The above in vitro results demonstrate that anti-DLL3 CAR-T cells can be stimulated and activated in vitro by DLL3 positive target cells and produce a range of cytokines associated with immune activation while achieving good killing effects on the target cells.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Furthermore, any theory, mechanism, proof, or finding stated herein is meant to further enhance understanding of the present invention and is not intended to limit the present invention in any way to such theory, mechanism, proof, or finding. While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character.

Sequence listing

<110> university of east China

SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY Co.,Ltd.

<120> an anti-DLL 3 scFv of whole human origin and its use in CART cell therapy

<160> 61

<170> SIPOSequenceListing 1.0

<210> 1

<211> 744

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 1

caggttcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60

tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc 120

cctggacaag ggcttgagtg gatgggaata atcaacccta gtggtggtag cacaagctac 180

gcaaagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac 240

atggaactga acagggtgac atctgacgac acggccgtgt attactgtgc gagaggcggt 300

ggggtgactg ggtttgacta ctggggccag ggaaccctgg tcaccgtctc ctcagggagt 360

gcatccgccc caacccttgg tggaggcggt tcaggcggag gtggcagcgg cggtggcggg 420

tcggacatcc agatgaccca gtctccatcc tccctgtctg catctttagg agacagagtc 480

accatcactt gccgggcaag tcagaccgtt agaacttatt taaattggta tcagcagaaa 540

ccagggaaag cccctaacct cctaatctat ggtgcatcca gtttgcaaag tggggtccca 600

tcaaggttca gtggcagtgg gtctgggaca gatttcactc taaccatcaa cagtctgcaa 660

cctgaggatt ttggaaccta ctactgtcaa cagagtgaca ctcccccgct cactttcggc 720

ggagggacca aggtggagat caaa 744

<210> 2

<211> 777

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 2

caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60

acctgtgcca tctccgggga cagtgtctct agcgacagtg ttgcttggag ctggatcaga 120

cagtccccat cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat 180

tatgattatg cagcatctgt gaaaagtcga ataagcatca acccagacac atccaagaac 240

cagttctccc tgcagttgaa ttctgtgact cccgaggaca cggctgtcta ttactgtgca 300

agagagcccc tccgttatgg gagcagctgg tgggatgctt ttgatatctg gggccaaggg 360

acaatgatca ccgtctcttc agggagtgca tccgccccaa cccttggtgg aggcggttca 420

ggcggaggtg gcagcggcgg tggcgggtcg cagtctgccc tgactcagcc tccctcagtg 480

tccgggtctc ctggacaggc agtcaccatc tcctgcactg gaaccagcag tgatgttggt 540

cgttataatt atgtctcctg gtaccaacaa cacccaggca aagtccccaa actcatcctt 600

tttgatgtct ctagtcggcc ctcaggggtt tctcatcgct tctctggctc caagtctggc 660

aacacggcct ccctgaccat ctctgggctc caggctgagg acgaggctga ttattactgc 720

acctcatata gaagtggcag cgaggtcttc ggcggaggga ccaagctgac cgtccta 777

<210> 3

<211> 69

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 3

gggagtgcat ccgccccaac ccttggtgga ggcggttcag gcggaggtgg cagcggcggt 60

ggcgggtcg 69

<210> 4

<211> 248

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Lys Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Asn Arg Val Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Val Thr Gly Phe Asp Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser Gly Ser Ala Ser Ala Pro Thr Leu Gly Gly

115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln

130 135 140

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val

145 150 155 160

Thr Ile Thr Cys Arg Ala Ser Gln Thr Val Arg Thr Tyr Leu Asn Trp

165 170 175

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Gly Ala

180 185 190

Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser

195 200 205

Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe

210 215 220

Gly Thr Tyr Tyr Cys Gln Gln Ser Asp Thr Pro Pro Leu Thr Phe Gly

225 230 235 240

Gly Gly Thr Lys Val Glu Ile Lys

245

<210> 5

<211> 259

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 5

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asp

20 25 30

Ser Val Ala Trp Ser Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu

35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Tyr Asp Tyr Ala

50 55 60

Ala Ser Val Lys Ser Arg Ile Ser Ile Asn Pro Asp Thr Ser Lys Asn

65 70 75 80

Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val

85 90 95

Tyr Tyr Cys Ala Arg Glu Pro Leu Arg Tyr Gly Ser Ser Trp Trp Asp

100 105 110

Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Ile Thr Val Ser Ser Gly

115 120 125

Ser Ala Ser Ala Pro Thr Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly

130 135 140

Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Pro Ser Val

145 150 155 160

Ser Gly Ser Pro Gly Gln Ala Val Thr Ile Ser Cys Thr Gly Thr Ser

165 170 175

Ser Asp Val Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro

180 185 190

Gly Lys Val Pro Lys Leu Ile Leu Phe Asp Val Ser Ser Arg Pro Ser

195 200 205

Gly Val Ser His Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser

210 215 220

Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys

225 230 235 240

Thr Ser Tyr Arg Ser Gly Ser Glu Val Phe Gly Gly Gly Thr Lys Leu

245 250 255

Thr Val Leu

<210> 6

<211> 23

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 6

Gly Ser Ala Ser Ala Pro Thr Leu Gly Gly Gly Gly Ser Gly Gly Gly

1 5 10 15

Gly Ser Gly Gly Gly Gly Ser

20

<210> 7

<211> 354

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 7

caggttcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60

tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc 120

cctggacaag ggcttgagtg gatgggaata atcaacccta gtggtggtag cacaagctac 180

gcaaagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac 240

atggaactga acagggtgac atctgacgac acggccgtgt attactgtgc gagaggcggt 300

ggggtgactg ggtttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354

<210> 8

<211> 321

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 8

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctttaggaga cagagtcacc 60

atcacttgcc gggcaagtca gaccgttaga acttatttaa attggtatca gcagaaacca 120

gggaaagccc ctaacctcct aatctatggt gcatccagtt tgcaaagtgg ggtcccatca 180

aggttcagtg gcagtgggtc tgggacagat ttcactctaa ccatcaacag tctgcaacct 240

gaggattttg gaacctacta ctgtcaacag agtgacactc ccccgctcac tttcggcgga 300

gggaccaagg tggagatcaa a 321

<210> 9

<211> 381

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 9

caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60

acctgtgcca tctccgggga cagtgtctct agcgacagtg ttgcttggag ctggatcaga 120

cagtccccat cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat 180

tatgattatg cagcatctgt gaaaagtcga ataagcatca acccagacac atccaagaac 240

cagttctccc tgcagttgaa ttctgtgact cccgaggaca cggctgtcta ttactgtgca 300

agagagcccc tccgttatgg gagcagctgg tgggatgctt ttgatatctg gggccaaggg 360

acaatgatca ccgtctcttc a 381

<210> 10

<211> 327

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 10

cagtctgccc tgactcagcc tccctcagtg tccgggtctc ctggacaggc agtcaccatc 60

tcctgcactg gaaccagcag tgatgttggt cgttataatt atgtctcctg gtaccaacaa 120

cacccaggca aagtccccaa actcatcctt tttgatgtct ctagtcggcc ctcaggggtt 180

tctcatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240

caggctgagg acgaggctga ttattactgc acctcatata gaagtggcag cgaggtcttc 300

ggcggaggga ccaagctgac cgtccta 327

<210> 11

<211> 118

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 11

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Lys Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Asn Arg Val Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Val Thr Gly Phe Asp Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser

115

<210> 12

<211> 107

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 12

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Val Arg Thr Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile

35 40 45

Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Ser Asp Thr Pro Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 13

<211> 127

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 13

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asp

20 25 30

Ser Val Ala Trp Ser Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu

35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Tyr Asp Tyr Ala

50 55 60

Ala Ser Val Lys Ser Arg Ile Ser Ile Asn Pro Asp Thr Ser Lys Asn

65 70 75 80

Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val

85 90 95

Tyr Tyr Cys Ala Arg Glu Pro Leu Arg Tyr Gly Ser Ser Trp Trp Asp

100 105 110

Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Ile Thr Val Ser Ser

115 120 125

<210> 14

<211> 109

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 14

Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln

1 5 10 15

Ala Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr

20 25 30

Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Val Pro Lys Leu

35 40 45

Ile Leu Phe Asp Val Ser Ser Arg Pro Ser Gly Val Ser His Arg Phe

50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu

65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Thr Ser Tyr Arg Ser Gly

85 90 95

Ser Glu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105

<210> 15

<211> 8

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 15

Gly Tyr Thr Phe Thr Ser Tyr Tyr

1 5

<210> 16

<211> 8

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 16

Ile Asn Pro Ser Gly Gly Ser Thr

1 5

<210> 17

<211> 11

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 17

Ala Arg Gly Gly Gly Val Thr Gly Phe Asp Tyr

1 5 10

<210> 18

<211> 6

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 18

Gln Thr Val Arg Thr Tyr

1 5

<210> 19

<211> 3

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 19

Gly Ala Ser

1

<210> 20

<211> 9

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 20

Gln Gln Ser Asp Thr Pro Pro Leu Thr

1 5

<210> 21

<211> 10

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 21

Gly Asp Ser Val Ser Ser Asp Ser Val Ala

1 5 10

<210> 22

<211> 9

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 22

Thr Tyr Tyr Arg Ser Lys Trp Tyr Tyr

1 5

<210> 23

<211> 17

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 23

Ala Arg Glu Pro Leu Arg Tyr Gly Ser Ser Trp Trp Asp Ala Phe Asp

1 5 10 15

Ile

<210> 24

<211> 9

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 24

Ser Ser Asp Val Gly Arg Tyr Asn Tyr

1 5

<210> 25

<211> 3

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 25

Asp Val Ser

1

<210> 26

<211> 9

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 26

Thr Ser Tyr Arg Ser Gly Ser Glu Val

1 5

<210> 27

<211> 1621

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 27

Arg Ala Ala Arg Ala His Gln Thr Leu Thr Asp Gln Thr Val Pro Phe

1 5 10 15

His Gly Ser Phe Leu Gln Ser Pro Ser Ser Thr Arg Ala Ala Thr Met

20 25 30

Glu Trp Ser Trp Val Phe Leu Phe Phe Leu Ser Val Thr Thr Gly Val

35 40 45

His Ser Asp Ile Glu Glu Glu Leu Gln Ile Ile Gln Pro Asp Lys Ser

50 55 60

Val Leu Val Ala Ala Gly Glu Thr Ala Thr Leu Arg Cys Thr Ile Thr

65 70 75 80

Ser Leu Phe Pro Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro

85 90 95

Gly Arg Val Leu Ile Tyr Asn Gln Arg Gln Gly Pro Phe Pro Arg Val

100 105 110

Thr Thr Val Ser Asp Thr Thr Lys Arg Asn Asn Met Asp Phe Ser Ile

115 120 125

Arg Ile Gly Asn Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Ile

130 135 140

Lys Phe Arg Lys Gly Ser Pro Asp Asp Val Glu Phe Lys Ser Gly Ala

145 150 155 160

Gly Thr Glu Leu Ser Val Arg Ala Lys Pro Ser Ser Gly Asp Lys Thr

165 170 175

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser

180 185 190

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg

195 200 205

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro

210 215 220

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

225 230 235 240

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val

245 250 255

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr

260 265 270

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr

275 280 285

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu

290 295 300

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys

305 310 315 320

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser

325 330 335

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp

340 345 350

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser

355 360 365

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala

370 375 380

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

385 390 395 400

Ser Arg Pro Leu Thr Arg Pro Trp Ile Gln Ile Cys Cys Ala Phe Leu

405 410 415

Pro Ala Ile Cys Cys Leu Pro Leu Pro Arg Ala Phe Leu Asp Pro Gly

420 425 430

Arg Cys His Ser His Cys Pro Phe Leu Ile Lys Gly Asn Cys Ile Ala

435 440 445

Leu Ser Glu Val Ser Phe Tyr Ser Gly Gly Trp Gly Gly Ala Gly Gln

450 455 460

Gln Gly Gly Gly Leu Gly Arg Gln Gln Ala Cys Trp Gly Cys Gly Gly

465 470 475 480

Leu Tyr Gly Tyr Pro Gly Ala Glu Glu Leu Thr Arg Phe Leu Leu Gly

485 490 495

Gln Lys Glu Ala Gly Thr Ser Pro Ser Leu His Thr Leu Ser Thr Pro

500 505 510

Leu Val Leu Ser Ser Ser Pro Thr His Arg Thr Leu Ile Ala Gln Glu

515 520 525

Gly Ser Ala Phe Asn Pro Thr Arg Ser Thr Trp Ser Gly Leu Ser Leu

530 535 540

Pro His Gln Pro Thr Lys Pro Asn Leu Ala Ser Lys Ser Gly Lys Lys

545 550 555 560

Leu Lys Gln Asp Arg Leu Leu Ser Ala Glu Gly Glu Lys Met Pro Pro

565 570 575

Thr Cys Glu Glu Val Met Arg Glu Ile Ile Glu Phe Gly His Asp Leu

580 585 590

Arg Pro Ser Trp Pro Ser Ser Ala Ser Ser Leu Thr Asp Ser Leu Arg

595 600 605

Ser Val Val Arg Leu Arg Arg Ala Val Ser Ala His Ser Lys Ala Val

610 615 620

Ile Arg Leu Ser Thr Glu Ser Gly Asp Asn Ala Gly Lys Asn Met Ala

625 630 635 640

Lys Gly Gln Gln Lys Ala Arg Asn Arg Lys Lys Ala Ala Leu Leu Ala

645 650 655

Phe Phe His Arg Leu Arg Pro Pro Asp Glu His His Lys Asn Arg Arg

660 665 670

Ser Ser Gln Arg Trp Arg Asn Pro Thr Gly Leu Arg Tyr Gln Ala Phe

675 680 685

Pro Pro Gly Ser Ser Leu Val Arg Ser Pro Val Pro Thr Leu Pro Leu

690 695 700

Thr Gly Tyr Leu Ser Ala Phe Leu Pro Ser Gly Ser Val Ala Leu Ser

705 710 715 720

His Ser Ser Arg Cys Arg Tyr Leu Ser Ser Val Val Val Arg Ser Lys

725 730 735

Leu Gly Cys Val His Glu Pro Pro Val Gln Pro Asp Arg Cys Ala Leu

740 745 750

Ser Gly Asn Tyr Arg Leu Glu Ser Asn Pro Val Arg His Asp Leu Ser

755 760 765

Pro Leu Ala Ala Ala Thr Gly Asn Arg Ile Ser Arg Ala Arg Tyr Val

770 775 780

Gly Gly Ala Thr Glu Phe Leu Lys Trp Trp Pro Asn Tyr Gly Tyr Thr

785 790 795 800

Arg Arg Thr Val Phe Gly Ile Cys Ala Leu Leu Lys Pro Val Thr Phe

805 810 815

Gly Lys Arg Val Gly Ser Ser Ser Gly Lys Gln Thr Thr Ala Gly Ser

820 825 830

Gly Gly Phe Phe Val Cys Lys Gln Gln Ile Thr Arg Arg Lys Lys Gly

835 840 845

Ser Gln Glu Asp Pro Leu Ile Phe Ser Thr Gly Ser Asp Ala Gln Trp

850 855 860

Asn Glu Asn Ser Arg Gly Ile Leu Val Met Arg Leu Ser Lys Arg Ile

865 870 875 880

Phe Thr Ile Leu Leu Asn Lys Ser Phe Lys Ser Ile Ser Ile Tyr Glu

885 890 895

Thr Trp Ser Asp Ser Tyr Gln Cys Leu Ile Ser Glu Ala Pro Ile Ser

900 905 910

Ala Ile Cys Leu Phe Arg Ser Ser Ile Val Ala Leu Gly Gly Gly Gly

915 920 925

Arg Gly Leu Pro Arg Glu Glu Gly Val Ala Asp Ser Tyr Gln Ala Ile

930 935 940

Ala Pro Ser Ser Ser Gln Lys Val Arg Glu Pro Arg Leu Met Arg Ala

945 950 955 960

Leu Leu Val Asp Gln Leu Val Ile Leu Asn Phe Cys Phe Ala Thr Glu

965 970 975

Arg Ser Ala Leu Ser Gly Arg Cys Val Ile Ser Phe Asn Ser Ala Lys

980 985 990

Val Arg Phe Ile Gln Gln Ser Arg Arg Pro Val Lys Ser Ala Cys Ser

995 1000 1005

Ala Ser Val Thr Thr Asn Pro Ile Leu Ile Arg Lys Thr His Arg Ala

1010 1015 1020

Ser Asn Glu Thr Ala Ile Tyr Ser Tyr Gln Asp Tyr Gln Tyr His Ile

1025 1030 1035 1040

Phe Glu Lys Ala Val Ser Val Met Lys Glu Lys Thr His Arg Gly Ser

1045 1050 1055

Ser Ile Gly Trp Gln Asp Pro Gly Ile Gly Leu Arg Phe Arg Leu Val

1060 1065 1070

Gln His Gln Tyr Asn Leu Leu Ile Ser Pro Arg Gln Lys Gly Tyr Gln

1075 1080 1085

Val Arg Asn His His Glu Arg Leu Asn Pro Val Arg Met Ala Lys Ala

1090 1095 1100

Tyr Ala Phe Leu Ser Arg Leu Val Gln Gln Ala Ser His Tyr Ala Arg

1105 1110 1115 1120

His Gln Asn His Ser His Gln Pro Asn Arg Tyr Ser Phe Val Ile Ala

1125 1130 1135

Pro Glu Arg Asp Glu Ile Arg Asp Arg Cys Lys Asp Asn Tyr Lys Gln

1140 1145 1150

Glu Ser Asn Ala Thr Gly Ala Gly Thr Leu Pro Ala His Gln Gln Tyr

1155 1160 1165

Phe His Leu Asn Gln Asp Ile Leu Leu Ile Pro Gly Met Leu Phe Ser

1170 1175 1180

Arg Gly Ser Gln Trp Val Thr Met His His Gln Glu Tyr Gly Asn Ala

1185 1190 1195 1200

Trp Ser Glu Glu Ala Ile Pro Ser Ala Ser Leu Val Pro Ser His Leu

1205 1210 1215

His His Trp Gln Arg Tyr Leu Cys His Val Ser Glu Thr Thr Leu Ala

1220 1225 1230

His Arg Ala Ser His Thr Ile Asp Arg Leu Ser His Leu Ile Ala Arg

1235 1240 1245

His Tyr Arg Glu Pro Ile Tyr Thr His Ile Asn Gln His Pro Cys Trp

1250 1255 1260

Asn Leu Ile Ala Ala Ser Ser Lys Thr Phe Pro Val Glu Tyr Gly Ser

1265 1270 1275 1280

His Pro Leu Tyr Tyr Cys Leu Cys Lys Gln Thr Val Leu Leu Phe Met

1285 1290 1295

Met Ile Tyr Phe Tyr Leu Val Gln Cys Asn Ile Arg Asp Phe Glu Thr

1300 1305 1310

Gln Arg Gly Phe Pro Pro Pro Pro Ile Ile Glu Ala Phe Ile Arg Val

1315 1320 1325

Ile Val Ser Ala Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys

1330 1335 1340

Gly Phe Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys Lys

1345 1350 1355 1360

Pro Leu Leu Ser His Pro Ile Lys Ile Gly Val Ser Arg Gly Pro Phe

1365 1370 1375

Val Ser Arg Val Ser Val Met Thr Val Lys Thr Ser Asp Thr Cys Ser

1380 1385 1390

Ser Arg Arg Arg Ser Gln Leu Val Cys Lys Arg Met Pro Gly Ala Asp

1395 1400 1405

Lys Pro Val Arg Ala Arg Gln Arg Val Leu Ala Gly Val Gly Ala Gly

1410 1415 1420

Leu Thr Met Arg His Gln Ser Arg Leu Tyr Glu Cys Thr Ile Cys Gly

1425 1430 1435 1440

Val Lys Tyr Arg Thr Asp Ala Gly Glu Asn Thr Ala Ser Asp Trp Leu

1445 1450 1455

Leu Glu Arg Ser Arg Ser Arg Gly Ala Gly Ala Arg Ala Cys Pro Trp

1460 1465 1470

Ala Pro Arg Ala Arg Thr Pro Pro His Pro Ser Cys Gly Met Cys Val

1475 1480 1485

Ser Gly Val Glu Ser Pro Gln Ala Pro Gln Gln Ala Glu Val Cys Lys

1490 1495 1500

Ala Cys Ile Ser Ile Ser Gln Gln Pro Gly Val Glu Ser Pro Gln Ala

1505 1510 1515 1520

Pro Gln Gln Ala Glu Val Cys Lys Ala Cys Ile Ser Ile Ile Gly Gln

1525 1530 1535

Pro Ser Arg Pro Leu Arg Pro Ser Arg Pro Leu Arg Pro Val Pro Pro

1540 1545 1550

Ile Leu Arg Pro Met Ala Asp Phe Phe Leu Phe Met Gln Arg Pro Arg

1555 1560 1565

Pro Pro Arg Pro Leu Ser Tyr Ser Arg Ser Ser Glu Glu Ala Phe Leu

1570 1575 1580

Glu Ala Ala Phe Ala Lys Thr Ser Leu Gly Pro Pro Leu Lys Thr Pro

1585 1590 1595 1600

Trp Pro Pro Pro Gln Ser Ile Asn Leu Pro Gly Lys Trp Val Gln Lys

1605 1610 1615

Tyr Met Pro Gln Gly

1620

<210> 28

<211> 227

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 28

gtagtcttat gcaatactct tgtagtcttg caacatggta acgatgagtt agcaacatgc 60

cttacaagga gagaaaaagc accgtgcatg ccgattggtg gaagtaaggt ggtacgatcg 120

tgccttatta ggaaggcaac agacgggtct gacatggatt ggacgaacca ctgaattgcc 180

gcattgcaga gatattgtat ttaagtgcct agctcgatac ataaacg 227

<210> 29

<211> 180

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 29

ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac 60

tgcttaagcc tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt 120

gtgactctgg taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca 180

<210> 30

<211> 353

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 30

atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgcgatgg gaaaaaattc 60

ggttaaggcc agggggaaag aaaaaatata aattaaaaca tatagtatgg gcaagcaggg 120

agctagaacg attcgcagtt aatcctggcc tgttagaaac atcagaaggc tgtagacaaa 180

tactgggaca gctacaacca tcccttcaga caggatcaga agaacttaga tcattatata 240

atacagtagc aaccctctat tgtgtgcatc aaaggataga gataaaagac accaaggaag 300

ctttagacaa gatagaggaa gagcaaaaca aaagtaagac caccgcacag caa 353

<210> 31

<211> 233

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 31

aggagctttg ttccttgggt tcttgggagc agcaggaagc actatgggcg cagcctcaat 60

gacgctgacg gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt 120

gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg gcatcaagca 180

gctccaggca agaatcctgg ctgtggaaag atacctaaag gatcaacagc tcc 233

<210> 32

<211> 495

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 32

tggggatttg gggttgctct ggaaaactca tttgcaccac tgctgtgcct tggaatgcta 60

gttggagtaa taaatctctg gaacagattg gaatcacacg acctggatgg agtgggacag 120

agaaattaac aattacacaa gcttaataca ctccttaatt gaagaatcgc aaaaccagca 180

agaaaagaat gaacaagaat tattggaatt agataaatgg gcaagtttgt ggaattggtt 240

taacataaca aattggctgt ggtatataaa attattcata atgatagtag gaggcttggt 300

aggtttaaga atagtttttg ctgtactttc tatagtgaat agagttaggc agggatattc 360

accattatcg tttcagaccc acctcccaac cccgagggga cccgacaggc ccgaaggaat 420

agaagaagaa ggtggagaga gagacagaga cagatccatt cgattagtga acggatctcg 480

acggtatcgg ttaac 495

<210> 33

<211> 118

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 33

ttttaaaaga aaagggggga ttggggggta cagtgcaggg gaaagaatag tagacataat 60

agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaattca aaatttta 118

<210> 34

<211> 1178

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 34

gctccggtgc ccgtcagtgg gcagagcgca catcgcccac agtccccgag aagttggggg 60

gaggggtcgg caattgaacc ggtgcctaga gaaggtggcg cggggtaaac tgggaaagtg 120

atgtcgtgta ctggctccgc ctttttcccg agggtggggg agaaccgtat ataagtgcag 180

tagtcgccgt gaacgttctt tttcgcaacg ggtttgccgc cagaacacag gtaagtgccg 240

tgtgtggttc ccgcgggcct ggcctcttta cgggttatgg cccttgcgtg ccttgaatta 300

cttccacctg gctgcagtac gtgattcttg atcccgagct tcgggttgga agtgggtggg 360

agagttcgag gccttgcgct taaggagccc cttcgcctcg tgcttgagtt gaggcctggc 420

ctgggcgctg gggccgccgc gtgcgaatct ggtggcacct tcgcgcctgt ctcgctgctt 480

tcgataagtc tctagccatt taaaattttt gatgacctgc tgcgacgctt tttttctggc 540

aagatagtct tgtaaatgcg ggccaagatc tgcacactgg tatttcggtt tttggggccg 600

cgggcggcga cggggcccgt gcgtcccagc gcacatgttc ggcgaggcgg ggcctgcgag 660

cgcggccacc gagaatcgga cgggggtagt ctcaagctgg ccggcctgct ctggtgcctg 720

gcctcgcgcc gccgtgtatc gccccgccct gggcggcaag gctggcccgg tcggcaccag 780

ttgcgtgagc ggaaagatgg ccgcttcccg gccctgctgc agggagctca aaatggagga 840

cgcggcgctc gggagagcgg gcgggtgagt cacccacaca aaggaaaagg gcctttccgt 900

cctcagccgt cgcttcatgt gactccactg agtaccgggc gccgtccagg cacctcgatt 960

agttctcgag cttttggagt acgtcgtctt taggttgggg ggaggggttt tatgcgatgg 1020

agtttcccca cactgagtgg gtggagactg aagttaggcc agcttggcac ttgatgtaat 1080

tctccttgga atttgccctt tttgagtttg gatcttggtt cattctcaag cctcagacag 1140

tggttcaaag tttttttctt ccatttcagg tgtcgtga 1178

<210> 35

<211> 63

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 35

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60

ccg 63

<210> 36

<211> 141

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 36

accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60

tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 120

gacttcgcct gtgatatcta c 141

<210> 37

<211> 66

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 37

atctgggcgc ccttggccgg gacttgtggg gtccttctcc tgtcactggt tatcaccctt 60

tactgc 66

<210> 38

<211> 126

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 38

aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa 60

actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt 120

gaactg 126

<210> 39

<211> 336

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 39

agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60

tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120

cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180

gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240

cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300

tacgacgccc ttcacatgca ggccctgccc cctcgc 336

<210> 40

<211> 591

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 40

aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct 60

ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt 120

atggctttca ttttctcctc cttgtataaa tcctggttgc tgtctcttta tgaggagttg 180

tggcccgttg tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc aacccccact 240

ggttggggca ttgccaccac ctgtcagctc ctttccggga ctttcgcttt ccccctccct 300

attgccacgg cggaactcat cgccgcctgc cttgcccgct gctggacagg ggctcggctg 360

ttgggcactg acaattccgt ggtgttgtcg gggaaatcat cgtcctttcc ttggctgctc 420

gcctgtgttg ccacctggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc 480

aatccagcgg accttccttc ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt 540

cgccttcgcc ctcagacgag tcggatctcc ctttgggccg cctccccgcc t 591

<210> 41

<211> 132

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 41

aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca 60

aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct 120

tatcatgtct gg 132

<210> 42

<211> 164

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 42

atcccgcccc taactccgcc catcccgccc ctaactccgc ccagttccgc ccattctccg 60

ccccatggct gactaatttt ttttatttat gcagaggccg aggccgcctc ggcctctgag 120

ctattccaga agtagtgagg aggctttttt ggatagactt ttgc 164

<210> 43

<211> 73

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 43

Val Val Leu Cys Asn Thr Leu Val Val Leu Gln His Gly Asn Asp Glu

1 5 10 15

Leu Ala Thr Cys Leu Thr Arg Arg Glu Lys Ala Pro Cys Met Pro Ile

20 25 30

Gly Gly Ser Lys Val Val Arg Ser Cys Leu Ile Arg Lys Ala Thr Asp

35 40 45

Gly Ser Asp Met Asp Trp Thr Asn His Ile Ala Ala Leu Gln Arg Tyr

50 55 60

Cys Ile Val Pro Ser Ser Ile His Lys

65 70

<210> 44

<211> 57

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 44

Gly Leu Ser Gly Thr Arg Ser Glu Pro Gly Ser Ser Leu Ala Asn Gly

1 5 10 15

Thr His Cys Leu Ser Leu Asn Lys Ala Cys Leu Glu Cys Phe Lys Cys

20 25 30

Val Pro Val Cys Cys Val Thr Leu Val Thr Arg Asp Pro Ser Asp Pro

35 40 45

Phe Ser Gln Cys Gly Lys Ser Leu Ala

50 55

<210> 45

<211> 107

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 45

Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Arg Asp

1 5 10 15

Gly Lys Lys Phe Gly Gly Gln Gly Glu Arg Lys Asn Ile Asn Asn Ile

20 25 30

Tyr Gly Gln Ala Gly Ser Asn Asp Ser Gln Leu Ile Leu Ala Cys Lys

35 40 45

His Gln Lys Ala Val Asp Lys Tyr Trp Asp Ser Tyr Asn His Pro Phe

50 55 60

Arg Gln Asp Gln Lys Asn Leu Asp His Tyr Ile Ile Gln Gln Pro Ser

65 70 75 80

Ile Val Cys Ile Lys Gly Arg Lys Thr Pro Arg Lys Leu Thr Arg Arg

85 90 95

Lys Ser Lys Thr Lys Val Arg Pro Pro His Ser

100 105

<210> 46

<211> 76

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 46

Arg Ser Phe Val Pro Trp Val Leu Gly Ser Ser Arg Lys His Tyr Gly

1 5 10 15

Arg Ser Leu Asn Asp Ala Asp Gly Thr Gly Gln Thr Ile Ile Val Trp

20 25 30

Tyr Ser Ala Ala Ala Glu Gln Phe Ala Glu Gly Tyr Gly Ala Thr Ala

35 40 45

Ser Val Ala Thr His Ser Leu Gly His Gln Ala Ala Pro Gly Lys Asn

50 55 60

Pro Gly Cys Gly Lys Ile Pro Lys Gly Ser Thr Ala

65 70 75

<210> 47

<211> 158

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 47

Trp Gly Phe Gly Val Ala Leu Glu Asn Ser Phe Ala Pro Leu Leu Cys

1 5 10 15

Leu Gly Met Leu Val Gly Val Ile Asn Leu Trp Asn Arg Leu Glu Ser

20 25 30

His Asp Leu Asp Gly Val Gly Gln Arg Asn Gln Leu His Lys Leu Asn

35 40 45

Thr Leu Leu Asn Arg Ile Ala Lys Pro Ala Arg Lys Glu Thr Arg Ile

50 55 60

Ile Gly Ile Arg Met Gly Lys Phe Val Glu Leu Val His Asn Lys Leu

65 70 75 80

Ala Val Val Tyr Lys Ile Ile His Asn Asp Ser Arg Arg Leu Gly Arg

85 90 95

Phe Lys Asn Ser Phe Cys Cys Thr Phe Tyr Ser Glu Ser Ala Gly Ile

100 105 110

Phe Thr Ile Ile Val Ser Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg

115 120 125

Gln Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln

130 135 140

Ile His Ser Ile Ser Glu Arg Ile Ser Thr Val Ser Val Asn

145 150 155

<210> 48

<211> 37

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 48

Phe Lys Lys Arg Gly Asp Trp Gly Val Gln Cys Arg Gly Lys Asn Ser

1 5 10 15

Arg His Asn Ser Asn Arg His Thr Asn Arg Ile Thr Lys Thr Asn Tyr

20 25 30

Lys Ile Gln Asn Phe

35

<210> 49

<211> 382

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 49

Ala Pro Val Pro Val Ser Gly Gln Ser Ala His Arg Pro Gln Ser Pro

1 5 10 15

Arg Ser Trp Gly Glu Gly Ser Ala Ile Glu Pro Val Pro Arg Glu Gly

20 25 30

Gly Ala Gly Thr Gly Lys Val Met Ser Cys Thr Gly Ser Ala Phe Phe

35 40 45

Pro Arg Val Gly Glu Asn Arg Ile Val Gln Ser Pro Thr Phe Phe Phe

50 55 60

Ala Thr Gly Leu Pro Pro Glu His Arg Val Pro Cys Val Val Pro Ala

65 70 75 80

Gly Leu Ala Ser Leu Arg Val Met Ala Leu Ala Cys Leu Glu Leu Leu

85 90 95

Pro Pro Gly Cys Ser Thr Phe Leu Ile Pro Ser Phe Gly Leu Glu Val

100 105 110

Gly Gly Arg Val Arg Gly Leu Ala Leu Lys Glu Pro Leu Arg Leu Val

115 120 125

Leu Glu Leu Arg Pro Gly Leu Gly Ala Gly Ala Ala Ala Cys Glu Ser

130 135 140

Gly Gly Thr Phe Ala Pro Val Ser Leu Leu Ser Ile Ser Leu Pro Phe

145 150 155 160

Lys Ile Phe Asp Asp Leu Leu Arg Arg Phe Phe Ser Gly Lys Ile Val

165 170 175

Leu Met Arg Ala Lys Ile Cys Thr Leu Val Phe Arg Phe Leu Gly Pro

180 185 190

Arg Ala Ala Thr Gly Pro Val Arg Pro Ser Ala His Val Arg Arg Gly

195 200 205

Gly Ala Cys Glu Arg Gly His Arg Glu Ser Asp Gly Gly Ser Leu Lys

210 215 220

Leu Ala Gly Leu Leu Trp Cys Leu Ala Ser Arg Arg Arg Val Ser Pro

225 230 235 240

Arg Pro Gly Arg Gln Gly Trp Pro Gly Arg His Gln Leu Arg Glu Arg

245 250 255

Lys Asp Gly Arg Phe Pro Ala Leu Leu Gln Gly Ala Gln Asn Gly Gly

260 265 270

Arg Gly Ala Arg Glu Ser Gly Arg Val Ser His Pro His Lys Gly Lys

275 280 285

Gly Pro Phe Arg Pro Gln Pro Ser Leu His Val Thr Pro Leu Ser Thr

290 295 300

Gly Arg Arg Pro Gly Thr Ser Ile Ser Ser Arg Ala Phe Gly Val Arg

305 310 315 320

Arg Leu Val Gly Gly Arg Gly Phe Met Arg Trp Ser Phe Pro Thr Leu

325 330 335

Ser Gly Trp Arg Leu Lys Leu Gly Gln Leu Gly Thr Cys Asn Ser Pro

340 345 350

Trp Asn Leu Pro Phe Leu Ser Leu Asp Leu Gly Ser Phe Ser Ser Leu

355 360 365

Arg Gln Trp Phe Lys Val Phe Phe Phe His Phe Arg Cys Arg

370 375 380

<210> 50

<211> 21

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 50

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro

20

<210> 51

<211> 47

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 51

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala

1 5 10 15

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly

20 25 30

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr

35 40 45

<210> 52

<211> 22

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 52

Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu

1 5 10 15

Val Ile Thr Leu Tyr Cys

20

<210> 53

<211> 42

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 53

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

1 5 10 15

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

20 25 30

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu

35 40

<210> 54

<211> 112

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 54

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly

1 5 10 15

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr

20 25 30

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys

35 40 45

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys

50 55 60

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg

65 70 75 80

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala

85 90 95

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

100 105 110

<210> 55

<211> 197

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 55

Asn Gln Pro Leu Asp Tyr Lys Ile Cys Glu Arg Leu Thr Gly Ile Leu

1 5 10 15

Asn Tyr Val Ala Pro Phe Thr Leu Cys Gly Tyr Ala Ala Leu Met Pro

20 25 30

Leu Tyr His Ala Ile Ala Ser Arg Met Ala Phe Ile Phe Ser Ser Leu

35 40 45

Tyr Lys Ser Trp Leu Leu Ser Leu Tyr Glu Glu Leu Trp Pro Val Val

50 55 60

Arg Gln Arg Gly Val Val Cys Thr Val Phe Ala Asp Ala Thr Pro Thr

65 70 75 80

Gly Trp Gly Ile Ala Thr Thr Cys Gln Leu Leu Ser Gly Thr Phe Ala

85 90 95

Phe Pro Leu Pro Ile Ala Thr Ala Glu Leu Ile Ala Ala Cys Leu Ala

100 105 110

Arg Cys Trp Thr Gly Ala Arg Leu Leu Gly Thr Asp Asn Ser Val Val

115 120 125

Leu Ser Gly Lys Ser Ser Ser Phe Pro Trp Leu Leu Ala Cys Val Ala

130 135 140

Thr Trp Ile Leu Arg Gly Thr Ser Phe Cys Tyr Val Pro Ser Ala Leu

145 150 155 160

Asn Pro Ala Asp Leu Pro Ser Arg Gly Leu Leu Pro Ala Leu Arg Pro

165 170 175

Leu Pro Arg Leu Arg Leu Arg Pro Gln Thr Ser Arg Ile Ser Leu Trp

180 185 190

Ala Ala Ser Pro Pro

195

<210> 56

<211> 43

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 56

Asn Leu Phe Ile Ala Ala Tyr Asn Gly Tyr Lys Ser Asn Ser Ile Thr

1 5 10 15

Asn Phe Thr Asn Lys Ala Phe Phe Ser Leu His Ser Ser Cys Gly Leu

20 25 30

Ser Lys Leu Ile Asn Val Ser Tyr His Val Trp

35 40

<210> 57

<211> 50

<212> PRT

<213> Artificial sequence (Artificial Sequence)

<400> 57

Ile Pro Pro Leu Thr Pro Pro Ile Pro Pro Leu Thr Pro Pro Ser Ser

1 5 10 15

Ala His Ser Pro Pro His Gly Leu Ile Phe Phe Ile Tyr Ala Glu Ala

20 25 30

Glu Ala Ala Ser Ala Ser Glu Leu Phe Gln Lys Gly Gly Phe Phe Gly

35 40 45

Thr Phe

50

<210> 58

<211> 42

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 58

accggcgtgc actccgatat ccaggttcag ctggtgcagt ct 42

<210> 59

<211> 42

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 59

tgtgtgagtt ttgtctccgg atttgatctc caccttggtc cc 42

<210> 60

<211> 43

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 60

accggcgtgc actccgatat ccaggtacag ctgcagcagt cag 43

<210> 61

<211> 42

<212> DNA

<213> Artificial sequence (Artificial Sequence)

<400> 61

tgtgtgagtt ttgtctccgg ataggacggt cagcttggtc cc 42

Claims

1. An anti-DLL 3 scFv, wherein the anti-DLL 3 scFv is capable of specifically binding to DLL3;

the amino acid sequence of the CDR of the heavy chain in the anti-DLL 3 scFv comprises CDR1 shown as SEQ ID NO.15, CDR2 shown as SEQ ID NO.16 and CDR3 shown as SEQ ID NO. 17; the CDR amino acid sequence of the light chain in the anti-DLL 3 scFv comprises CDR1 shown as SEQ ID NO.18, CDR2 shown as SEQ ID NO.19 and CDR3 shown as SEQ ID NO. 20;

Or,

the CDR amino acid sequence of the heavy chain in the anti-DLL 3 scFv comprises CDR1 shown as SEQ ID NO.21, CDR2 shown as SEQ ID NO.22 and CDR3 shown as SEQ ID NO. 23; the CDR amino acid sequence of the light chain in the anti-DLL 3 scFv comprises CDR1 shown as SEQ ID NO.24, CDR2 shown as SEQ ID NO.25 and CDR3 shown as SEQ ID NO. 26.

2. The anti-DLL 3 scFv of claim 1, wherein the anti-DLL 3 scFv comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region and the light chain variable region are linked by a flexible linker;

or,

3. The anti-DLL 3 scFv of claim 2, wherein the nucleotide sequence of the heavy chain variable region is set forth in SEQ ID No.7 and the nucleotide sequence of the light chain variable region is set forth in SEQ ID No. 8;

or alternatively

4. The anti-DLL 3 scFv of claim 1, wherein the amino acid sequence of the anti-DLL 3 scFv is set forth in SEQ ID No. 4;

or,

as shown in SEQ ID NO. 5.

5. A nucleic acid molecule whose nucleotide sequence encodes the amino acid sequence of the anti-DLL 3 scFv according to claim 4; the nucleotide sequence is shown as SEQ ID NO.1 or SEQ ID NO. 2.

6. An anti-DLL 3 CAR, wherein the anti-DLL 3 CAR has a structure of CD8leader-DLL3 scFv-CD8 Hinge-CD8 TM-co-stimulatory domain-intracellular signal peptide, comprising a CD8leader membrane receptor signal peptide, the single chain variable fragment of claim 1, a CD8 Hinge chimeric receptor Hinge, a CD8 TM chimeric receptor transmembrane region, a co-stimulatory domain, and an intracellular signal peptide, in series; the costimulatory domain is 4-1BB; the intracellular signal peptide is CD3 zeta,

1) The amino acid sequence of the CD8leader is SEQ ID NO.50;

2) The amino acid sequence of CD8 finger is SEQ ID NO.51;

3) The amino acid sequence of the CD8 TM transmembrane region is SEQ ID NO.52;

4) 41BB co-stimulatory domain amino acid sequence is SEQ ID NO.53;

5) The CD3 zeta amino acid sequence is SEQ ID NO.54;

the method comprises the following steps:

1) The nucleotide sequence of the CD8 leader is SEQ ID NO.35;

2) The nucleotide sequence of CD8 finger is SEQ ID NO.36;

3) The nucleotide sequence of the CD8 TM transmembrane region is SEQ ID NO.37;

4) 41BB co-stimulatory domain nucleotide sequence is SEQ ID NO.38;

5) The nucleotide sequence of CD3 zeta is SEQ ID NO.39.

7. A plasmid comprising the nucleotide sequence encoding the heavy chain variable region and the nucleotide sequence encoding the light chain variable region of the DLL3scFv of claim 3.

8. A recombinant lentiviral vector comprising the nucleotide sequence encoding the heavy chain variable region and the nucleotide sequence encoding the light chain variable region of the DLL3scFv of claim 3.

9. Use of an anti-DLL 3scFv according to claim 1, or a nucleic acid molecule according to claim 5, or an anti-DLL 3 CAR according to claim 6, or a plasmid according to claim 7, or a recombinant lentiviral vector according to claim 8 for the preparation of an anti-tumour medicament, the tumour being small cell lung cancer.